Prognostic parameters on baseline and interim [18F]FDG-PET/computed tomography in diffuse large B-cell lymphoma patients

被引:3
作者
Czibor, Sandor [1 ]
Carr, Robert [2 ]
Redondo, Francisca [3 ]
Auewarakul, Chirayu U. [4 ]
Cerci, Juliano J. [5 ]
Paez, Diana [6 ]
Fanti, Stefano [7 ]
Gyorke, Tamas [1 ]
机构
[1] Semmelweis Univ, Med Imaging Ctr, Dept Nucl Med, Budapest, Hungary
[2] Kings Coll London, Guys & St Thomas Hosp, Dept Hematol, London, England
[3] Fdn Arturo Lopez Perez, Oncol Clin, Santiago, Chile
[4] Chulabhorn Royal Acad, HRH Princess Chulabhorn Coll Med Sci, Fac Med & Publ Hlth, Bangkok, Thailand
[5] PET CT Dept Quanta Diagnost & Terapia, Curitiba, Brazil
[6] IAEA, Dept Nucl Sci & Applicat, Div Human Hlth, Nucl Med & Diagnost Imaging Sect, Vienna, Austria
[7] Univ Bologna, Policlin S Orsola, Metropolitan Nucl Med, Bologna, Italy
关键词
diffuse large B-cell lymphoma; Deauville score; PET; metabolic tumor volume; ratio PET; METABOLIC TUMOR VOLUME; PROGRESSION-FREE SURVIVAL; HODGKIN-LYMPHOMA; RESPONSE ASSESSMENT; FDG-PET/CT; PREDICTION; CRITERIA; IPI;
D O I
10.1097/MNM.0000000000001664
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective2-[F-18]fluoro-2-deoxy-d-glucose PET/computed tomography ([F-18]FDG-PET/CT) is a widely used imaging method in the management of diffuse large B-cell lymphomas (DLBCL). Our aim was to investigate the prognostic performance of different PET biomarkers in a multicenter setting. MethodsWe investigated baseline volumetric values [metabolic tumor volume (MTV) and total lesion glycolysis (TLG), also normalized for body weight] segmented with three different methods [>SUV4 (glob4); 41% isocontour (41pc), and a gradient-based lesion growing algorithm (grad)] and interim parameters [Deauville score, maximal standardized uptake value (Delta SUVmax), modified qPET, and ratio PET (rPET)] alongside clinical parameters (stage, revised International Prognostic Index), using 24-month progression-free survival as the clinical endpoint. Receiver operating characteristics analyses were performed to define optimal cutoff points for the continuous PET parameters. ResultsA total of 107 diffuse large B-cell lymphoma patients were included (54 women; mean age: 53.7 years). MTV and TLG calculations showed good correlation among glob4, 41pc, and grad methods; however, optimal cutoff points were markedly different.Significantly different PFS was observed between low- and high-risk groups according to baseline MTV, body weight-adjusted (bwa) MTV, TLG, bwaTLG, as well as interim parameters Deauville score, Delta SUVmax, mqPET, and rPET. Univariate Cox regression analyses showed hazard ratios (HRs) lowest for bwaMTVglob4 (HR = 2.3) and highest for rPET (HR = 9.09). In a multivariate Cox-regression model, rPET was shown to be an independent predictor of PFS (P = 0.041; HR = 9.15). Combined analysis showed that Delta SUVmax positive patients with high MTV formed a group with distinctly poor PFS (35.3%). ConclusionBaseline MTV and TLG values and optimal cutoff points achieved with different segmentation methods varied markedly and showed a limited prognostic impact. Interim PET/CT parameters provided more accurate prognostic information with semiquantitative 'Deauville-like' parameters performing best in the present study.
引用
收藏
页码:291 / 301
页数:11
相关论文
共 42 条
  • [1] EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies
    Aide, Nicolas
    Lasnon, Charline
    Veit-Haibach, Patrick
    Sera, Terez
    Sattler, Bernhard
    Boellaard, Ronald
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S17 - S31
  • [2] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
    Alizadeh, AA
    Eisen, MB
    Davis, RE
    Ma, C
    Lossos, IS
    Rosenwald, A
    Boldrick, JG
    Sabet, H
    Tran, T
    Yu, X
    Powell, JI
    Yang, LM
    Marti, GE
    Moore, T
    Hudson, J
    Lu, LS
    Lewis, DB
    Tibshirani, R
    Sherlock, G
    Chan, WC
    Greiner, TC
    Weisenburger, DD
    Armitage, JO
    Warnke, R
    Levy, R
    Wilson, W
    Grever, MR
    Byrd, JC
    Botstein, D
    Brown, PO
    Staudt, LM
    [J]. NATURE, 2000, 403 (6769) : 503 - 511
  • [3] Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET)
    Annunziata, Salvatore
    Cuccaro, Annarosa
    Calcagni, Maria Lucia
    Hohaus, Stefan
    Giordano, Alessandro
    Rufini, Vittoria
    [J]. ANNALS OF NUCLEAR MEDICINE, 2016, 30 (08) : 588 - 592
  • [4] Correlation of 18-fluorodeoxyglucose PET/computed tomography parameters and clinical features to predict outcome for diffuse large B-cell lymphoma
    Baratto, Lucia
    Wu, Fengyu
    Minamimoto, Ryogo
    Hatami, Negin
    Liang, Tie
    Sabile, Jean
    Advani, Ranjana H.
    Mittra, Erik
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2021, 42 (07) : 792 - 799
  • [5] Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden
    Barrington, Sally E.
    Meignan, Michel
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (08) : 1096 - 1102
  • [6] Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
    Barrington, Sally F.
    Mikhaeel, N. George
    Kostakoglu, Lale
    Meignan, Michel
    Hutchings, Martin
    Mueeller, Stefan P.
    Schwartz, Lawrence H.
    Zucca, Emanuele
    Fisher, Richard I.
    Trotman, Judith
    Hoekstra, Otto S.
    Hicks, Rodney J.
    O'Doherty, Michael J.
    Hustinx, Roland
    Biggi, Alberto
    Cheson, Bruce D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) : 3048 - +
  • [7] Prospective International Cohort Study Demonstrates Inability of Interim PET to Predict Treatment Failure in Diffuse Large B-Cell Lymphoma
    Carr, Robert
    Fanti, Stefano
    Paez, Diana
    Cerci, Juliano
    Gyoerke, Tamas
    Redondo, Francisca
    Morris, Tim P.
    Meneghetti, Claudio
    Auewarakul, Chirayu
    Nair, Reena
    Gorospe, Charity
    Chung, June-Key
    Kuzu, Isinsu
    Celli, Monica
    Gujral, Sumeet
    Padua, Rose Ann
    Dondi, Maurizio
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (12) : 1936 - 1944
  • [8] Prognostic significance of total metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy
    Chang, Chin-Chuan
    Cho, Shih-Feng
    Chuang, Ya-Wen
    Lin, Chia-Yang
    Chang, Shu-Min
    Hsu, Wen-Ling
    Huang, Ying-Fong
    [J]. ONCOTARGET, 2017, 8 (59) : 99587 - 99600
  • [9] Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
    Chapuy, Bjoern
    Stewart, Chip
    Dunford, Andrew J.
    Kim, Jaegil
    Kamburov, Atanas
    Redd, Robert A.
    Lawrence, Mike S.
    Roemer, Margaretha G. M.
    Li, Amy J.
    Ziepert, Marita
    Staiger, Annette M.
    Wala, Jeremiah A.
    Ducar, Matthew D.
    Leshchiner, Ignaty
    Rheinbay, Ester
    Taylor-Weiner, Amaro
    Coughlin, Caroline A.
    Hess, Julian M.
    Pedamallu, Chandra S.
    Livitz, Dimitri
    Rosebrock, Daniel
    Rosenberg, Mara
    Tracy, Adam A.
    Horn, Heike
    van Hummelen, Paul
    Feldman, Andrew L.
    Link, Brian K.
    Novak, Anne J.
    Cerhan, James R.
    Habermann, Thomas M.
    Siebert, Reiner
    Rosenwald, Andreas
    Thorner, Aaron R.
    Meyerson, Matthew L.
    Golub, Todd R.
    Beroukhim, Rameen
    Wulf, Gerald G.
    Ott, German
    Rodig, Scott J.
    Monti, Stefano
    Neuberg, Donna S.
    Loeffler, Markus
    Pfreundschuh, Michael
    Truemper, Lorenz
    Getz, Gad
    Shipp, Margaret A.
    [J]. NATURE MEDICINE, 2018, 24 (05) : 679 - +
  • [10] Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
    Cheson, Bruce D.
    Fisher, Richard I.
    Barrington, Sally F.
    Cavalli, Franco
    Schwartz, Lawrence H.
    Zucca, Emanuele
    Lister, T. Andrew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) : 3059 - +